RT Journal Article
SR Electronic
T1 Design and methods of the Population Assessment of Tobacco and Health (PATH) Study
JF Tobacco Control
JO Tob Control
FD BMJ Publishing Group Ltd
SP 371
OP 378
DO 10.1136/tobaccocontrol-2016-052934
VO 26
IS 4
A1 Andrew Hyland
A1 Bridget K Ambrose
A1 Kevin P Conway
A1 Nicolette Borek
A1 Elizabeth Lambert
A1 Charles Carusi
A1 Kristie Taylor
A1 Scott Crosse
A1 Geoffrey T Fong
A1 K Michael Cummings
A1 David Abrams
A1 John P Pierce
A1 James Sargent
A1 Karen Messer
A1 Maansi Bansal-Travers
A1 Ray Niaura
A1 Donna Vallone
A1 David Hammond
A1 Nahla Hilmi
A1 Jonathan Kwan
A1 Andrea Piesse
A1 Graham Kalton
A1 Sharon Lohr
A1 Nick Pharris-Ciurej
A1 Victoria Castleman
A1 Victoria R Green
A1 Greta Tessman
A1 Annette Kaufman
A1 Charles Lawrence
A1 Dana M van Bemmel
A1 Heather L Kimmel
A1 Ben Blount
A1 Ling Yang
A1 Barbara O'Brien
A1 Cindy Tworek
A1 Derek Alberding
A1 Lynn C Hull
A1 Yu-Ching Cheng
A1 David Maklan
A1 Cathy L Backinger
A1 Wilson M Compton
YR 2017
UL http://tobaccocontrol.bmj.com/content/26/4/371.abstract
AB Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration's (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat.Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study's design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use.Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA's regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation's burden of tobacco-related death and disease.